Rational heterodoxy: Cholesterol reformation of the amyloid doctrine

Ageing Research Reviews

Volumn 12, Issue 1, 2013, Pages 282-288

  Castello, Michael A ^a   Soriano, Salvador ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cholesterol; Niemann Pick type c disease

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; CHOLESTEROL METABOLISM; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; HOMEOSTASIS; HUMAN; NERVE CELL; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NIEMANN PICK DISEASE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW;

AMYLOID; ANIMALS; CHOLESTEROL; HUMANS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84867600744     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2012.06.007     Document Type: Review

References (101)

1. Alzheimer's Association, 2011. 2011 Alzheimer's disease facts and figures. Alzheimer's and Dementia 7, 208-244.
2. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathologica 2009, 118:167-179.
3. Auer I.A., Schmidt M.L., Lee V.M., Curry B., Suzuki K., Shin R.W., Pentchev P.G., Carstea E.D., Trojanowski J.Q. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathologica 1995, 90:547-551.
4. Barceló-Coblijn G., Golovko M.Y., Weinhofer I., Berger J., Murphy E.J. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. Journal of Neurochemistry 2007, 101:132-141.
5. Bar-On P., Crews L., Koob A.O., Mizuno H., Adame A., Spencer B., Masliah E. Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson's disease. Journal of Neurochemistry 2008, 105:1656-1667.
6. Barrett P.J., et al. The Amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012, 336:1168-1171.
7. Bayh, E., 2011. National Alzheimer's Prevention Act, USC.
8. Beel A.J., Mobley C.K., Kim H.J., Tian F., Hadziselimovic A., Jap B., Prestegard J.H., Sanders C.R. Structural studies of the transmembrane C-Terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. Biochemistry 2008, 47:9428-9446.
9. Beel A.J., Sakakura M., Barrett P.J., Sanders C.R. Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer's disease relationships?. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2010, 1801:975-982.
10. Benilova I., Karran E., De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nature Neuroscience 2012.
11. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
12. Block M.L., Hong J.-S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Progress in Neurobiology 2005, 76:77-98.
13. Bommer G.T., MacDougald O.A. Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus. Cell Metabolism 2011, 13:241-247.
14. Borbon I.A., Erickson R.P. Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's. Journal of Applied Genetics 2011, 52:213-218.
15. Bosco D.A., Fowler D.M., Zhang Q., Nieva J., Powers E.T., Wentworth P., Lerner R.A., Kelly J.W. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nature Chemical Biology 2006, 2:249-253.
16. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience 2009, 10:333-344.
17. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., Mathews P.M., Noble W., Matsuoka Y., Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances β-amyloid production in vivo. The Journal of Neuroscience 2003, 23:5645-5649.
18. Castellani R.J., Lee H., Siedlak S.L., Nunomura A., Hayashi T., Nakamura M., Zhu X., Perry G., Smith M.A. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. Journal of Alzheimer's Disease 2009, 18:447-452.
19. Cirera-Salinas, D., Pauta, M., Allen, R.M., Salerno, A.G., Ramírez, C.M., Chamorro-Jorganes, A., Wanschel, A.C., Lasuncion, M.A., Morales-Ruiz, M., Suarez, Y., Baldan, A., Esplugues, E., Fernández-Hernando, C., 2012. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle (Georgetown, Tex.) 11.
20. Conejero-Goldberg C., Hyde T.M., Chen S., Dreses-Werringloer U., Herman M.M., Kleinman J.E., Davies P., Goldberg T.E. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Molecular Psychiatry 2011, 16:836-847.
21. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
22. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., Turner A.J. Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein. Proceedings of the National Academy of Sciences 2003, 100:11735-11740.
23. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M., Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988, 38:1682-1687.
24. Currais, A., Hortobágyi, T., Soriano, S., 2009. The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer's disease. PMID: 20157524.
25. del Toro D., Xifró X., Pol A., Humbert S., Saudou F., Canals J.M., Alberch J. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. Journal of Neurochemistry 2010, 115:153-167.
26. Delrieu J., Ousset P.J., Caillaud C., Vellas B. Clinical trials in Alzheimer's disease': immunotherapy approaches. Journal of Neurochemistry 2011.
27. Dubois B., Feldman H.H., Jacova C., Cummings J.L., DeKosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet Neurology 2010, 9:1118-1127.
28. Förstl H., Haass C., Hemmer B., Meyer B., Halle M. Boxing-acute complications and late sequelae: from concussion to dementia. Deutsches Ärzteblatt International 2010, 107:835-839.
29. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., Edwards R.H. Lipid rafts mediate the synaptic localization of α-synuclein. The Journal of Neuroscience 2004, 24:6715-6723.
30. Galpern W.R., Lang A.E. Interface between tauopathies and synucleinopathies: a tale of two proteins. Annals of Neurology 2006, 59:449-458.
31. Ghribi O., Larsen B., Schrag M., Herman M.M. High cholesterol content in neurons increases BACE. β-amyloid, and phosphorylated tau levels in rabbit hippocampus. Experimental Neurology 2006, 200:460-467.
32. Golde T.E., Petrucelli L., Lewis J. Targeting Aβ and tau in Alzheimer's disease, an early interim report. Experimental Neurology 2010, 223:252-266.
33. Greenberg S.M., Rebeck G.W., Vonsattel J.P., Gomez-Isla T., Hyman B.T. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Annals of Neurology 1995, 38:254-259.
34. Grimm M.O.W., Grimm H.S., Pätzold A.J., Zinser E.G., Halonen R., Duering M., Tschäpe J.A., De Strooper B., Müller U., Shen J., Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nature Cell Biology 2005, 7:1118-1123.
35. Grimm M.O.W., Grimm H.S., Hartmann T. Amyloid beta as a regulator of lipid homeostasis. Trends in Molecular Medicine 2007, 13:337-344.
36. Grösgen S., Grimm M.O.W., Frieß P., Hartmann T. Role of amyloid beta in lipid homeostasis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2010, 1801:966-974.
37. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences 1986, 83:4913-4917.
38. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
39. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
40. Hendriks L., van Duijn C.M., Cras P., Cruts M., Van Hul W., van Harskamp F., Warren A., McInnis M.G., Antonarakis S.E., Martin J.J. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nature Genetics 1992, 1:218-221.
41. Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. The Journal of Neuroscience 2010, 30:16755-16762.
42. Herrup K. The involvement of cell cycle events in the pathogenesis of Alzheimer's disease. Alzheimer's Research & Therapy 2010, 2:13.
43. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.-C. et al., 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet advance online publication. PMID: 21460840.
44. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A.R. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
45. Jarrett J.T., Berger E.P., Lansbury P.T. The C-terminus of the β protein is critical in amyloidogenesisa. Annals of the New York Academy of Sciences 1993, 695:144-148.
46. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5819-5824.
47. Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., et al. Genetic Evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 2010, 5:e13950.
48. Jonsson, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
49. Josephs K.A., Tsuboi Y., Cookson N., Watt H., Dickson D.W. Apolipoprotein E {varepsilon}4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Archives of Neurology 2004, 61:1579-1584.
50. Jun G., Naj A.C., Beecham G.W., Wang L.-S., Buros J., Gallins P.J., Buxbaum J.D., Ertekin-Taner N., Fallin M.D., Friedland R., Inzelberg R., Kramer P., Rogaeva E., St George-Hyslop P., Cantwell L.B., Dombroski B.A., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Lunetta K.L., Martin E.R., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Beekly D., Cupples L.A., Hakonarson H., Kukull W., Foroud T.M., Haines J., Mayeux R., Farrer L.A., Pericak-Vance M.A., Schellenberg G.D. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Archives of Neurology 2010, 67:1473-1484.
51. Kågedal K., Kim W.S., Appelqvist H., Chan S., Cheng D., Agholme L., Barnham K., McCann H., Halliday G., Garner B. Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2010, 1801:831-838.
52. Karran E., Mercken M., Strooper B.D. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery 2011, 10:698-712.
53. Kirsch C., Eckert G.P., Koudinov A.R., Müller W.E. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003, 2(36 Suppl.):S113-S119.
54. Koudinov A.R., Koudinova N.V. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. The FASEB Journal 2001.
55. Lee H., Zhu X., Castellani R.J., Nunomura A., Perry G., Smith M.A. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. Journal of Pharmacology and Experimental Therapeutics 2007, 321:823-829.
56. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.-S., Wang B., Cole S.L., Herz J., Muglia L., Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
57. Liu J.-P., Tang Y., Zhou S., Toh B.H., McLean C., Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Molecular and Cellular Neurosciences 2010, 43:33-42.
58. Liu Q., Trotter J., Zhang J., Peters M.M., Cheng H., Bao J., Han X., Weeber E.J., Bu G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. Journal of Neuroscience 2010, 30:17068-17078.
59. Lloyd-Evans E., Platt F.M. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 2010, 11:419-428.
60. Love S., Bridges L.R., Case C.P. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995, 118(Pt 1):119-129.
61. Mandas A., Abete C., Putzu P.F., la Colla P., Dessì S., Pani A. Changes in cholesterol metabolism-related gene expression in peripheral blood mononuclear cells from Alzheimer patients. Lipids in Health and Disease 2012, 11:39.
62. Martinez M., Brice A., Vaughan J.R., Zimprich A., Breteler M.M.B., Meco G., Filla A., Farrer M.J., Bétard C., Singleton A., Hardy J., De Michele G., Bonifati V., Oostra B.A., Gasser T., Wood N.W., Dürr A. Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 136B:72-74.
63. Masterman T., Hillert J. The telltale scan: APOE epsilon4 in multiple sclerosis. Lancet Neurology 2004, 3:331.
64. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences 1985, 82:4245-4249.
65. Mattson M.P. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Experimental Gerontology 2009, 44:625-633.
66. Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS & Neurological Disorders - Drug Targets 2009, 8:7-15.
67. Naj, A.C., Jun, G., Beecham, G.W., Wang, L.-S., Vardarajan, B.N. et al., 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet advance online publication.
68. Nunes A., Pressey S.N.R., Cooper J.D., Soriano S. Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis. Neurobiology of Disease 2011, 42:349-359.
69. Ota M., Fujii T., Nemoto K., Tatsumi M., Moriguchi Y., Hashimoto R., Sato N., Iwata N., Kunugi H. A polymorphism of the ABCA1 gene confers susceptibility to schizophrenia and related brain changes. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:1877-1883.
70. Pappolla M.A., Smith M.A., Bryant-Thomas T., Bazan N., Petanceska S., Perry G., Thal L.J., Sano M., Refolo L.M. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radical Biology and Medicine 2002, 33:173-181.
71. Phelix C.F., LeBaron R.G., Roberson D.J., Villanueva R.E., Villareal G., Rahimi O.B., Siedlak S., Zhu X., Perry G. Transcriptome-to-metabolome biosimulation reveals human hippocampal hypometabolism with age and Alzheimer's disease. International Journal of Knowledge Discovery in Bioinformatics 2011, 2.
72. Prasanthi, J.R.P., Larson, T., Schommer, J., Ghribi, O., 2011. Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus.
73. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., Morris J.C. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging 2009, 30:1026-1036.
74. Rodríguez-Rodríguez E., Vázquez-Higuera J.L., Sánchez-Juan P., Mateo I., Pozueta A., Martínez-García A., Frank A., Valdivieso F., Berciano J., Bullido M.J., Combarros O. Epistasis between intracellular cholesterol trafficking-related genes (NPC1 and ABCA1) and Alzheimer's disease risk. Journal of Alzheimer's Disease 2010, 21:619-625.
75. Roy S., Zhang B., Lee V.M.-Y., Trojanowski J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathologica 2005, 109:5-13.
76. Saito Y., Suzuki K., Nanba E., Yamamoto T., Ohno K., Murayama S. Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Annals of Neurology 2002, 52:351-355.
77. Salloway S., Sperling R., Keren R., Porsteinsson A.P., van Dyck C.H., Tariot P.N., Gilman S., Arnold D., Abushakra S., Hernandez C., Crans G., Liang E., Quinn G., Bairu M., Pastrak A., Cedarbaum J.M. For the ELND005-AD201 Investigators, A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77:1253-1262.
78. Sato Y., Suzuki I., Nakamura T., Bernier F., Aoshima K., Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. Journal of Lipid Research 2012, 53:567-576.
79. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine 1996, 2:864-870.
80. Schreurs B.G. The effects of cholesterol on learning and memory. Neuroscience & Biobehavioral Reviews 2010, 34:1366-1379.
81. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
82. Seneff S., Davidson R., Mascitelli L. Might cholesterol sulfate deficiency contribute to the development of autistic spectrum disorder?. Medical Hypotheses 2011.
83. Shafaati M., Marutle A., Pettersson H., Lövgren-Sandblom A., Olin M., Pikuleva I., Winblad B., Nordberg A., Björkhem I. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. Journal of Lipid Research 2011, 52:1004-1010.
84. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Archives of Neurology 2011, 68:1385-1392.
85. Shie F.-S., Jin L.-W., Cook D.G., Leverenz J.B., LeBoeuf R.C. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002, 13:455-459.
86. Sikora D.M., Pettit-Kekel K., Penfield J., Merkens L.S., Steiner R.D. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics Part A 2006, 140:1511-1518.
87. Sparks D.L., Kuo Y.-M., Roher A., Martin T., Lukas R.J. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Annals of the New York Academy of Sciences 2000, 903:335-344.
88. Stranahan A.M., Mattson M.P. Recruiting adaptive cellular stress responses for successful brain ageing. Nature Reviews Neuroscience 2012, 13:209-216.
89. Stranahan A.M., Cutler R.G., Button C., Telljohann R., Mattson M.P. Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. Journal of Neurochemistry 2011, 118:611-615.
90. Suzuki R., Lee K., Jing E., Biddinger S.B., McDonald J.G., Montine T.J., Craft S., Kahn C.R. Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metabolism 2010, 12:567-579.
91. Thelen K.M., Falkai P., Bayer T.A., Lütjohann D. Cholesterol synthesis rate in human hippocampus declines with aging. Neuroscience Letters 2006, 403:15-19.
92. Thirumangalakudi L., Prakasam A., Zhang R., Bimonte-Nelson H., Sambamurti K., Kindy M.S., Bhat N.R. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. Journal of Neurochemistry 2008, 106:475-485.
93. Treiber-Held S., Distl R., Meske V., Albert F., Ohm T.G. Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease. Journal of Pathology 2003, 200:95-103.
94. Uylings H.B.M., de Brabander J.M. Neuronal changes in normal human aging and Alzheimer's disease. Brain and Cognition 2002, 49:268-276.
95. Valdez C.M., Smith M.A., Perry G., Phelix C.F., Santamaria F. Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus 2010, 20(8):902-905.
96. van den Kommer T.N., Dik M.G., Comijs H.C., Fassbender K., Lütjohann D., Jonker C. Total cholesterol and oxysterols: early markers for cognitive decline in elderly?. Neurobiology of Aging 2009, 30:534-545.
97. Vance J.E. Lipid imbalance in the neurological disorder, Niemann-Pick C disease. FEBS Letters 2006, 580:5518-5524.
98. Vellas B. Tarenflurbil for Alzheimer's disease: a " shot on goal" that missed. Lancet Neurology 2010, 9:235-237.
99. Whitson J.S., Selkoe D.J., Cotman C.W. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 1989, 243:1488-1490.
100. Xu W.L., Atti A.R., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011, 76:1568-1574.
101. Zhang M., Wang X., Jiang F., Wang W., Vincent I., Bu B. Mitotic epitopes are incorporated into age-dependent neurofibrillary tangles in Niemann-Pick disease type C. Brain Pathology 2010, 20:367-377.